XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.1
Restructuring
3 Months Ended
Mar. 31, 2022
Restructuring and Related Activities [Abstract]  
Restructuring Restructuring
In 2019, Merck approved a global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate footprint. This program is a continuation of the Company’s plant rationalization and builds on prior restructuring programs. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $3.5 billion. The Company estimates that approximately 70% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately 30% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested.
The Company recorded total pretax costs of $127 million and $334 million in the first quarter of 2022 and 2021, respectively, related to restructuring program activities. Since inception of the Restructuring Program through March 31, 2022, Merck has recorded total pretax accumulated costs of approximately $2.8 billion. For the full year of 2022, the Company expects to record charges of approximately $400 million related to the Restructuring Program. For segment reporting, restructuring charges are unallocated expenses.
The following tables summarize the charges related to restructuring program activities by type of cost:
 Three Months Ended March 31, 2022
($ in millions)Separation
Costs
Accelerated
Depreciation
OtherTotal
Cost of sales$— $18 $28 $46 
Selling, general and administrative— 17 21 
Research and development— — 
Restructuring costs26 — 27 53 
$26 $29 $72 $127 
 Three Months Ended March 31, 2021
($ in millions)Separation
Costs
Accelerated
Depreciation
OtherTotal
Cost of sales$— $10 $17 $27 
Selling, general and administrative— — 
Research and development— — 
Restructuring costs229 — 68 297 
$229 $20 $85 $334 
Separation costs are associated with actual headcount reductions, as well as those headcount reductions which were probable and could be reasonably estimated.
Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the programs. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.
Other activity in 2022 and 2021 includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note 10) and share-based compensation.
The following table summarizes the charges and spending relating to restructuring program activities for the three months ended March 31, 2022:
($ in millions)Separation
Costs
Accelerated
Depreciation
OtherTotal
Restructuring reserves January 1, 2022
$596 $— $41 $637 
Expense26 29 72 127 
(Payments) receipts, net(68)— (45)(113)
Non-cash activity— (29)(39)(68)
Restructuring reserves March 31, 2022 (1)
$554 $— $29 $583 
(1)The remaining cash outlays are expected to be substantially completed by the end of 2023.